Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Gains from Sales and Divestitures (2020 - 2025)

Historic Gains from Sales and Divestitures for Beam Therapeutics (BEAM) over the last 6 years, with Q3 2025 value amounting to $783939.0.

  • Beam Therapeutics' Gains from Sales and Divestitures rose 3625.24% to $783939.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $783939.0, marking a year-over-year increase of 3625.24%. This contributed to the annual value of $1.3 million for FY2024, which is 17730.59% up from last year.
  • According to the latest figures from Q3 2025, Beam Therapeutics' Gains from Sales and Divestitures is $783939.0, which was up 3625.24% from $688359.0 recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Gains from Sales and Divestitures peaked at $1.3 million during Q4 2024, and registered a low of $283186.0 during Q1 2022.
  • For the 5-year period, Beam Therapeutics' Gains from Sales and Divestitures averaged around $558681.9, with its median value being $469531.0 (2023).
  • In the last 5 years, Beam Therapeutics' Gains from Sales and Divestitures crashed by 5843.78% in 2022 and then surged by 17730.59% in 2024.
  • Over the past 5 years, Beam Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $1.0 million in 2021, then crashed by 58.44% to $424303.0 in 2022, then rose by 10.66% to $469531.0 in 2023, then soared by 177.31% to $1.3 million in 2024, then tumbled by 39.79% to $783939.0 in 2025.
  • Its Gains from Sales and Divestitures was $783939.0 in Q3 2025, compared to $688359.0 in Q2 2025 and $607196.0 in Q1 2025.